{
    "nctId": "NCT00472693",
    "briefTitle": "Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer",
    "officialTitle": "A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "To determine progression-free survival among women receiving bevacizumab + ABI-007 given as second-line combination therapy for hormone receptive negative, Her-2 negative metastatic breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, aged 18 years or older and able to give informed consent.\n* Histologically- or cytologically-proven adenocarcinoma of the breast at time of first diagnosis\n* ECOG performance status 0 or 1\n* Life expectancy \\> 12 weeks\n* Stage IV disease and have at least one lesion measurable by standard RECIST criteria\n* Disease progression after at least one prior chemotherapy regimen for metastatic disease or within 12 months of adjuvant chemotherapy initiation.\n* All chemotherapy must be stopped \\> 2 weeks before enrollment.\n* Primary or metastatic tumor must be negative for estrogen and progesterone receptor expression. Testing must be done in a CLIA-approved laboratory.\n* Primary or metastatic tumor must have 0 or 1+ staining for HER2/neu identified immunohistochemically (IHC), by an approved method using one of the standard monoclonal or polyclonal antibodies (HercepTest, cb-11, PAb1, or TAB250), or if FISH status is known, it must be negative. Testing must be done in a CLIA-approved laboratory.\n* Left ventricular ejection fraction must be \\>= institutional lower limit of normal as determined by MUGA or echocardiogram\n* Patient must be able to comply with treatment and follow-up procedures:\n* Adequate bone marrow, liver and renal function; Absolute neutrophil count \\>= 1500/mm3; Hemoglobin \\>= 10 g/dl; Platelet count \\>= 100,000/mm3; Creatinine \\<= 2.0; PTT and either INR or PT \\< 1.5x normal; Total bilirubin \\<= 1.5 X upper limit of normal; AST, ALT, and alkaline phosphatase \\<= 2 X upper limit of normal (or \\<= 5X upper limit of normal if known liver metastases)\n* If female is of childbearing potential, pregnancy test must be negative and patient must be willing to use effective contraception while on treatment and for at least 3 months after the last dose of study medication\n\nExclusion Criteria:\n\n* Prior treatment with VEGF targeted therapy\n* Prior taxane therapy for metastatic disease or for adjuvant therapy within the previous 12 months\n* History of prior cancer, excluding carcinoma in situ of the cervix and non-melanoma skin cancers\n* Known CNS disease\n* Inadequately controlled hypertension (defined as systolic blood pressure\\>150 and/or diastolic blood pressure\\>100 mmHg on antihypertensive medications)\n* Any prior history of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association (NYHA) Grade II or greater congestive heart failure\n* History of myocardial infarction or unstable angina within 6 months prior to study enrollment\n* History of stroke or transient ischemic attack within 6 months prior to study enrollment\n* Significant vascular disease (e.g., aortic aneurysm, aortic dissection)\n* Symptomatic peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study\n* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment\n* Serious, non-healing wound, ulcer or bone fracture\n* Proteinuria at screening as demonstrated by either: Urine protein:creatinine (UPC) ratio \\>1.0 at screening OR Urine dipstick for proteinuria \\>2+ (patients discovered to have \\>2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \\<1g of protein in 24 hours to be eligible)\n* Patients with active infection\n* Women who are pregnant or lactating\n* Radiation therapy within 3 weeks of study entry\n* Patients with hypersensitivity to ABI-007, Chinese hamster ovary cell products, or other recombinant human antibodies\n* Baseline neuropathy \\> grade 2\n* Participation in an investigational study of an antineoplastic agent within 4 weeks of first infusion of this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}